Recent studies have centered on the convergence of GLP|GIP|glucagon receptor agonist therapies and DA neurotransmission. While GCGR activators are commonly employed for addressing type 2 diabetes mellitus, their potential impacts on motivation circuits, specifically mediated by dopaminergic pathw